Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Common Equity: 2017-2024

Historic Common Equity for Dianthus Therapeutics (DNTH) over the last 6 years, with Dec 2024 value amounting to $352.5 million.

  • Dianthus Therapeutics' Common Equity rose 61.72% to $546.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $546.5 million, marking a year-over-year increase of 61.72%. This contributed to the annual value of $352.5 million for FY2024, which is 108.73% up from last year.
  • Latest data reveals that Dianthus Therapeutics reported Common Equity of $352.5 million as of FY2024, which was up 108.73% from $168.9 million recorded in FY2023.
  • Dianthus Therapeutics' 5-year Common Equity high stood at $352.5 million for FY2024, and its period low was -$44.4 million during FY2022.
  • In the last 3 years, Dianthus Therapeutics' Common Equity had a median value of $168.9 million in 2023 and averaged $159.0 million.
  • Data for Dianthus Therapeutics' Common Equity shows a peak YoY skyrocketed of 480.61% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Dianthus Therapeutics' Common Equity stood at -$44.4 million in 2022, then surged by 480.61% to $168.9 million in 2023, then spiked by 108.73% to $352.5 million in 2024.